Published in CA Cancer J Clin on January 07, 2016
SGI-110 Plus Durvalumab/Tremelimumab in SCLC | NCT03085849
Dose Escalated Proton Beam Therapy or Photon Therapy for Esophageal Cancer (ES01) | NCT03234842
Complete Pathologic Response Rectal Cancers (CORSiCA) | NCT03351959
Nal-IRI(Nanoliposomal Irinotecan) Plus 5-FU/LV in Metastatic Biliary Tract Cancer | NCT03524508
Upfront Treatment With Chemotherapy and Bevacizumab in Advanced Ovarian Cancer | NCT03611179
Study of Porcine Fibrin Sealant in Preventing Cervical Anastomotic Leakage | NCT03847857
Nivolumab in Biochemically Recurrent dMMR Prostate Cancer | NCT04019964
Role of Preoperative Multislice Computed Tomography in Whipple's Operation. | NCT04582461
Developing a Test for the Detection of Ovarian Cancer | NCT04794322
Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. N Engl J Med (2016) 4.31
Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer. N Engl J Med (2016) 2.95
Integrated genomic characterization of oesophageal carcinoma. Nature (2017) 2.76
Limited heterogeneity of known driver gene mutations among the metastases of individual patients with pancreatic cancer. Nat Genet (2017) 2.42
TMPRSS2-ERG fusion co-opts master transcription factors and activates NOTCH signaling in primary prostate cancer. Nat Genet (2017) 1.43
MIIP remodels Rac1-mediated cytoskeleton structure in suppression of endometrial cancer metastasis. J Hematol Oncol (2016) 1.41
Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol (2017) 1.41
Pathologically decreased expression of miR-193a contributes to metastasis by targeting WT1-E-cadherin axis in non-small cell lung cancers. J Exp Clin Cancer Res (2016) 1.40
Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer. PLoS One (2017) 1.40
Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma. J Immunother Cancer (2017) 1.39
Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer. PLoS One (2017) 1.39
Molecular characterization of breast cancer CTCs associated with brain metastasis. Nat Commun (2017) 1.39
Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol (2016) 1.02
Pancreatic cancer biology and genetics from an evolutionary perspective. Nat Rev Cancer (2016) 0.98
Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol (2016) 0.94
Value: The Next Frontier in Cancer Care. Oncologist (2016) 0.92
Metallothionein-1G facilitates sorafenib resistance through inhibition of ferroptosis. Hepatology (2016) 0.91
Circadian Rhythm Disruption Promotes Lung Tumorigenesis. Cell Metab (2016) 0.90
Complete video-assisted thoracoscopic surgery (VATS) bronchial sleeve lobectomy. J Thorac Dis (2016) 0.89
Targeting bet bromodomain proteins in solid tumors. Oncotarget (2016) 0.89
The clinicopathological and prognostic significance of PD-L1 expression in gastric cancer: a meta-analysis of 10 studies with 1,901 patients. Sci Rep (2016) 0.88
Long non-coding RNA UCA1 is a predictive biomarker of cancer. Oncotarget (2016) 0.88
A divide-and-conquer strategy in tumor sampling enhances detection of intratumor heterogeneity in routine pathology: A modeling approach in clear cell renal cell carcinoma. F1000Res (2016) 0.88
Epidemiology of venous thromboembolism in the Framingham Heart Study. Thromb Res (2016) 0.88
Over-expression of ASIC1a promotes proliferation via activation of the β-catenin/LEF-TCF axis and is associated with disease outcome in liver cancer. Oncotarget (2017) 0.87
Leucocyte telomere length, genetic variants at the TERT gene region and risk of pancreatic cancer. Gut (2016) 0.87
(11)C-Choline PET/CT for restaging prostate cancer. Results from 4,426 scans in a single-centre patient series. Eur J Nucl Med Mol Imaging (2016) 0.87
Androgen receptor variation affects prostate cancer progression and drug resistance. Pharmacol Res (2016) 0.87
The sentinel node approach in gynaecological malignancies. Clin Transl Imaging (2016) 0.87
Genomic and Epigenomic Alterations in Cancer. Am J Pathol (2016) 0.86
Decreased expression of the long noncoding RNA LINC00261 indicate poor prognosis in gastric cancer and suppress gastric cancer metastasis by affecting the epithelial-mesenchymal transition. J Hematol Oncol (2016) 0.86
JQ1 suppresses tumor growth via PTEN/PI3K/AKT pathway in endometrial cancer. Oncotarget (2016) 0.86
An Unexpected Turn: My Life as a Cancer Advocate. Am J Gastroenterol (2016) 0.85
The high expression of long non-coding RNA PANDAR indicates a poor prognosis for colorectal cancer and promotes metastasis by EMT pathway. J Cancer Res Clin Oncol (2016) 0.85
Association of prostate volume with incidence and aggressiveness of prostate cancer. Res Rep Urol (2016) 0.85
PI3K pathway mutations are associated with longer time to local progression after radioembolization of colorectal liver metastases. Oncotarget (2017) 0.85
MicroRNA-320a inhibits breast cancer metastasis by targeting metadherin. Oncotarget (2016) 0.85
Role of targeted therapy in metastatic colorectal cancer. World J Gastrointest Oncol (2016) 0.85
Local triple-combination therapy results in tumour regression and prevents recurrence in a colon cancer model. Nat Mater (2016) 0.85
NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. J Natl Compr Canc Netw (2016) 0.85
Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial. J Clin Oncol (2016) 0.85
State of the science on prevention and screening to reduce melanoma incidence and mortality: The time is now. CA Cancer J Clin (2016) 0.85
PPARγ as a Novel Therapeutic Target in Lung Cancer. PPAR Res (2016) 0.84
PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction? J Immunother Cancer (2016) 0.84
Therapeutic management options for stage III non-small cell lung cancer. World J Clin Oncol (2017) 0.84
Immunotherapy for human papillomavirus-associated disease and cervical cancer: review of clinical and translational research. J Gynecol Oncol (2016) 0.83
Aurora A kinase regulates non-homologous end-joining and poly(ADP-ribose) polymerase function in ovarian carcinoma cells. Oncotarget (2017) 0.83
Progress in systemic therapy of advanced hepatocellular carcinoma. World J Gastroenterol (2016) 0.83
Prognostic role of platelet-lymphocyte ratio in colorectal cancer: A systematic review and meta-analysis. Medicine (Baltimore) (2016) 0.83
Validation of a Biomarker Panel and Longitudinal Biomarker Performance for Early Detection of Ovarian Cancer. Int J Gynecol Cancer (2016) 0.83
Genomic regulation of invasion by STAT3 in triple negative breast cancer. Oncotarget (2016) 0.83
How Precisely Can Prostate Cancer Be Managed? Int Neurourol J (2016) 0.83
Role of long noncoding RNA UCA1 as a common molecular marker for lymph node metastasis and prognosis in various cancers: a meta-analysis. Oncotarget (2016) 0.83
Discovery of Anticancer Agents of Diverse Natural Origin. Anticancer Res (2016) 0.83
An Arntl2-Driven Secretome Enables Lung Adenocarcinoma Metastatic Self-Sufficiency. Cancer Cell (2016) 0.83
TWIST1 drives cisplatin resistance and cell survival in an ovarian cancer model, via upregulation of GAS6, L1CAM, and Akt signalling. Sci Rep (2016) 0.83
The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability vs. PD-L1. J Gastrointest Oncol (2016) 0.83
Steroidogenic Metabolism of Galeterone Reveals a Diversity of Biochemical Activities. Cell Chem Biol (2017) 0.83
Molecular substratification of bladder cancer: moving towards individualized patient management. Ther Adv Urol (2016) 0.82
miRNA let-7b modulates macrophage polarization and enhances tumor-associated macrophages to promote angiogenesis and mobility in prostate cancer. Sci Rep (2016) 0.82
Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study. J Clin Oncol (2016) 0.82
Identification of an atypical etiological head and neck squamous carcinoma subtype featuring the CpG island methylator phenotype. EBioMedicine (2017) 0.82
Cancer stem cell markers predict a poor prognosis in renal cell carcinoma: a meta-analysis. Oncotarget (2016) 0.82
Editorial: On the Quality of Quality Metrics: Rethinking What Defines a Good Colonoscopy. Am J Gastroenterol (2016) 0.82
Circulating Tumor Cell Count Correlates with Colorectal Neoplasm Progression and Is a Prognostic Marker for Distant Metastasis in Non-Metastatic Patients. Sci Rep (2016) 0.82
Roles of Dietary Phytoestrogens on the Regulation of Epithelial-Mesenchymal Transition in Diverse Cancer Metastasis. Toxins (Basel) (2016) 0.82
Comparison of clinical outcomes of squamous cell carcinoma, adenocarcinoma, and adenosquamous carcinoma of the uterine cervix after definitive radiotherapy: a population-based analysis. J Cancer Res Clin Oncol (2016) 0.82
FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer. World J Gastroenterol (2016) 0.82
Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: Are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy? Gynecol Oncol (2017) 0.82
Identification of salivary metabolomic biomarkers for oral cancer screening. Sci Rep (2016) 0.82
Clinical value of nodal micrometastases in patients with non-small cell lung cancer: time for reconsideration? J Thorac Dis (2016) 0.82
Regular Aspirin Use Associates With Lower Risk of Colorectal Cancers With Low Numbers of Tumor-Infiltrating Lymphocytes. Gastroenterology (2016) 0.81
A perspective on anti-EGFR therapies targeting triple-negative breast cancer. Am J Cancer Res (2016) 0.81
RAS and BRAF in metastatic colorectal cancer management. J Gastrointest Oncol (2016) 0.81
Cisplatin induces the release of extracellular vesicles from ovarian cancer cells that can induce invasiveness and drug resistance in bystander cells. Philos Trans R Soc Lond B Biol Sci (2018) 0.81
Cancer Risk Factor Knowledge Among Young Adults. J Cancer Educ (2017) 0.81
Comprehensive profile of differentially expressed circular RNAs reveals that hsa_circ_0000069 is upregulated and promotes cell proliferation, migration, and invasion in colorectal cancer. Onco Targets Ther (2016) 0.81
Technical challenges in the isolation and analysis of circulating tumor cells. Oncotarget (2016) 0.81
Self-immolative nanoparticles for simultaneous delivery of microRNA and targeting of polyamine metabolism in combination cancer therapy. J Control Release (2016) 0.81
Spotlight on elotuzumab in the treatment of multiple myeloma: the evidence to date. Onco Targets Ther (2016) 0.81
Oncogenic Kras drives invasion and maintains metastases in colorectal cancer. Genes Dev (2017) 0.81
Targeting DNA Damage Response in the Radio(Chemo)therapy of Non-Small Cell Lung Cancer. Int J Mol Sci (2016) 0.81
Comparative Proteomic Analysis of Whole-Gut Lavage Fluid and Pancreatic Juice Reveals a Less Invasive Method of Sampling Pancreatic Secretions. Clin Transl Gastroenterol (2016) 0.81
Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence. ESMO Open (2016) 0.81
Cohesin mutations in human cancer. Biochim Biophys Acta (2016) 0.81
The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA. Nat Rev Urol (2016) 0.81
Rottlerin inhibits cell growth and invasion via down-regulation of Cdc20 in glioma cells. Oncotarget (2016) 0.81
Potential efficacy of therapies targeting intrahepatic lesions after sorafenib treatment of patients with hepatocellular carcinoma. BMC Cancer (2016) 0.81
The role of immune checkpoint inhibition in the treatment of ovarian cancer. Gynecol Oncol Res Pract (2016) 0.81
Postprostatectomy Erectile Dysfunction: A Review. World J Mens Health (2016) 0.81
A potential prognostic lncRNA signature for predicting survival in patients with bladder urothelial carcinoma. Oncotarget (2017) 0.81
Intrinsic Resistance to 5-Fluorouracil in a Brain Metastatic Variant of Human Breast Cancer Cell Line, MDA-MB-231BR. PLoS One (2016) 0.81
Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer. Nat Rev Clin Oncol (2016) 0.80
Skeletal Muscle Measures as Predictors of Toxicity, Hospitalization, and Survival in Patients with Metastatic Breast Cancer Receiving Taxane Based Chemotherapy. Clin Cancer Res (2016) 0.80
Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group. Haematologica (2016) 0.80
Role of Apigenin in Cancer Prevention via the Induction of Apoptosis and Autophagy. J Cancer Prev (2016) 0.80
Restitution of Tumor Suppressor MicroRNA-145 Using Magnetic Nanoformulation for Pancreatic Cancer Therapy. J Gastrointest Surg (2016) 0.80
Epithelial-to-Mesenchymal Transition in the Pathogenesis and Therapy of Head and Neck Cancer. Cancers (Basel) (2017) 0.80
The Role of microRNAs in the Diagnosis and Treatment of Pancreatic Adenocarcinoma. J Clin Med (2016) 0.80
MicroRNAs and epithelial-mesenchymal transition in prostate cancer. Oncotarget (2016) 0.80
Cancer statistics, 2015. CA Cancer J Clin (2015) 57.51
Cancer Statistics, 2017. CA Cancer J Clin (2017) 4.77
Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin (2016) 2.93
Breast cancer statistics, 2015: Convergence of incidence rates between black and white women. CA Cancer J Clin (2015) 1.70
Cancer statistics for Asian Americans, Native Hawaiians, and Pacific Islanders, 2016: Converging incidence in males and females. CA Cancer J Clin (2016) 1.53
Cancer statistics for African Americans, 2016: Progress and opportunities in reducing racial disparities. CA Cancer J Clin (2016) 1.28
2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin (2016) 0.96
Colorectal cancer statistics, 2017. CA Cancer J Clin (2017) 0.95
Cancer statistics: Breast cancer in situ. CA Cancer J Clin (2015) 0.91
Breast cancer statistics, 2017, racial disparity in mortality by state. CA Cancer J Clin (2017) 0.75
Disparities in liver cancer occurrence in the United States by race/ethnicity and state. CA Cancer J Clin (2017) 0.75
The burden of rare cancers in the United States. CA Cancer J Clin (2017) 0.75